Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra seeks FDA review transfer for ADX-2191 lymphoma drug, withdraws SPA protocol

Negative Impact 4 of 5 legal/regulatory

Aldeyra asked the FDA's Division of Ophthalmology to request that review of the ADX-2191 IND for primary vitreoretinal lymphoma move to the Division of Hematologic Malignancies 2, and it withdrew the Special Protocol Assessment for the planned trial. The company said the regulatory path is now uncertain and may be significantly delayed, and that the planned trial will need to be redesigned, which could raise costs and shorten its cash runway.

Key points

  • Aldeyra requested a review jurisdiction transfer to the FDA's Division of Hematologic Malignancies 2 (DHM2), announced November 9, 2026
  • The company withdrew the SPA protocol for ADX-2191 in PVRL, which the Division of Ophthalmology had previously agreed to
  • Aldeyra does not expect to start the planned trial while the request is pending; the FDA may deny the request or transfer the IND to another division
  • The filing warns of higher costs, a shorter cash runway and possible need for earlier capital raising

The filing

CompanyAldeyra Therapeutics, Inc. (ALDX)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:02 PM ET
Accession number0001193125-26-453537

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 5:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.